Phio Pharmaceuticals (PHIO) CFO Carson Receives 108,000-Share Award

What Happened
Carson Lisa Cabott, Chief Financial Officer of Phio Pharmaceuticals Corp. (PHIO), received an award of 108,000 shares on 2026-09-28 reported on a Form 4 filed 2026-09-29. The grant is reported at $0.00 per share (total reported value $0) because the award is in the form of restricted stock units (RSUs) rather than an open-market purchase. Per the filing, these RSU shares will vest on the first annual anniversary of the grant.

Key Details

• Transaction date: 2026-09-28; Form 4 filed: 2026-09-29 (timely filing).
• Transaction type/code: A — Grant/Award (acquisition of RSUs).
• Amount: 108,000 shares; reported price: $0.00; reported total value: $0.
• Vesting: Footnote F1 — shares underlying the RSUs will vest on the first annual anniversary of the grant.
• Footnote F2 indicates reported ownership figures include shares underlying unvested RSUs (specific post-transaction share total not provided in the summary supplied).
• No indication of a sale, open-market purchase, 10b5-1 plan, or tax-withholding action in the provided filing.

Context
RSU grants are a form of compensation and do not represent immediate buying or selling of stock — they convert into actual shares only upon vesting and are generally subject to forfeiture until then. For retail investors, such grants are routine executive compensation and not a direct near-term market signal; they do, however, align management pay with future company performance.